Epidermolysis Bullosa Acquisita

Understanding Epidermolysis Bullosa and Its Acquired Variant

The Epidermolysis bullosa (EB) represents a group of hereditary conditions characterized by blister formation, which are present from birth.

What is Epidermolysis Bullosa Acquisita (EBA)?

The Epidermolysis bullosa acquisita (EBA) is a disease defect that is rare. It manifests with the appearance of subepidermal tense blisters located specifically in areas subject to trauma physical trauma. A key differentiating factor is that, unlike EB, EBA is not inherited and usually manifests during adulthood.

EBA blisters tend to concentrate in areas that are easily damaged, such as the hands, feet, knees, elbows, and the gluteal region. Occasionally, there may be mucosal mucosa, involvement, causing blister formation in the oral cavity, nose, and eyes.

Illustrative Images of Epidermolysis Bullosa Acquisita

Close-up of a large blister on the skin as a sign of Epidermolysis bullosa acquisita. — Skin manifestation of Epidermolysis bullosa acquisita

Area of skin with tense blisters and erosions due to Epidermolysis bullosa acquisita. — Friction area lesion due to Epidermolysis bullosa acquisita

Detail of skin involvement with blister formation in Epidermolysis bullosa acquisita. — Blister formation in EBA

Skin with multiple blisters and epidermal detachment characteristic of Epidermolysis bullosa acquisita. — Skin sloughing associated with Epidermolysis bullosa acquisita

Blisters and scars on the hands, a common site of trauma in Epidermolysis bullosa acquisita. — Localized involvement in the hands due to EBA

Blisters on the feet, a weight-bearing area prone to friction, in a patient with Epidermolysis bullosa acquisita. — Foot lesions typical of Epidermolysis bullosa acquisita

It is essential to understand that while EB is a genetic condition present from birth, Epidermolysis bullosa acquisita is an autoimmune entity that requires a different diagnostic and therapeutic approach than when facing hereditary forms. The localization of damage in friction sites is a key indicator for suspecting EBA in adults.

Who Develops Epidermolysis Bullosa Acquisita (EBA) and Risk Factors?

Epidermolysis bullosa acquisita (EBA) generally manifests in the fourth and fifth decades of patients' lives. It affects both men and women of any ethnic background.

In some individuals with EBA, the coexistence of other autoimmune conditions has been observed, with Crohn's disease and systemic lupus erythematosus being the most frequent associations. Health problems such as amyloidosis, multiple myeloma, and, rarely, lung carcinoma and lymphoma are also reported. However, other patients only present with skin involvement without these comorbidities.

Understanding the Etiology of Epidermolysis Bullosa Acquisita

Researchers have identified the presence of Immunoglobulin G (IgG) autoantibodies directed against the NC1 domain of type VII collagen (Col7) in affected patients. Type VII collagen is a fundamental structural component of anchoring fibrils. These fibrils connect the epidermal basement membrane to the underlying dermis.

The destruction of these anchoring fibrils results in blister formation just below the epidermis, in a region called the lamina densa. This autoimmune process is the central mechanism that triggers EBA pathology.

Distinctive Clinical Presentations of Epidermolysis Bullosa Acquisita

EBA manifests through several well-differentiated clinical presentations, each with specific patterns of involvement and prognosis.

EBA Classification	Key Clinical Features
Classic Mechanobullous Form of EBA	This is the most prevalent variant of EBA in European populations. Appearance of vesicles and bullae (blisters) predominantly on the extensor surfaces of extremities such as hands, knees, knuckles, elbows, and ankles. Blisters on mucous membranes are fragile and rupture easily. Lesions heal leaving noticeable scarring and milia (small, pearly white papules). Clinically, it resembles the dystrophic form of inherited epidermolysis bullosa.
Non-Classic or Non-Mechanobullous Form of EBA	Presence of tense vesicles and extensive blisters that are not strictly confined to sites of trauma. Frequently affects the trunk and skin folds. It may present with generalized redness, pruritus (itching), and plaque formation. Scarring is less pronounced, with minimal milia formation. It presents clinical similarity to bullous pemphigoid.
Predominantly Mucous Membrane Form of EBA	Involvement of mucous membranes including the oral cavity, gums (gingival), palate, ocular conjunctivae, nasopharynx, esophagus, anal, and genital regions. It can lead to significant scarring of the mucous membranes, resulting in dysfunction of the affected areas. It is often confused with mucous membrane pemphigoid.
Brunsting-Perry EBA Type	It is a chronic and recurrent disease characterized by the appearance of blisters. Involvement is mainly limited to the head and neck. Its presentation is similar to Brunsting-Perry type mucous membrane pemphigoid.
IgA-EBA	Presents great similarity to linear IgA bullous dermatosis. Linear IgA deposits are observed at the basement membrane zone upon immunological testing. This variant tends to be more aggressive, particularly with scarring in the mucous membranes.

Diagnosis of Epidermolysis Bullosa Acquisita (EBA)

The definitive diagnosis of Epidermolysis Bullosa Acquisita (EBA) requires performing several specialized clinical and laboratory tests to confirm autoimmunity and characteristic dermal involvement.

Key Tests for EBA Diagnosis

To establish an accurate diagnosis of EBA, the following main analyses are required:

Skin Biopsy: This histopathological procedure will reveal the presence of a subepidermal blister, which indicates the separation between the epidermis and the dermis. Cells of a inflammatory infiltrate mixed inflammatory infiltrate are also observed in the dermis, and milia cysts and scars are common in older lesions.
Direct Immunofluorescence (DIF) of Skin Biopsy: DIF analysis typically shows the linear deposition of Immunoglobulin G (IgG, more frequent than IgM or IgA) and C3 along the dermal-epidermal junction. It is important to note that blood blood vessels vessels are not usually involved in this deposition pattern.
Indirect Immunofluorescence (IIF) of Serum: This test detects the presence of circulating IgG autoantibodies, generally at a low titer, which are specifically directed against the basement membrane.

There are additional tests only available at specialized academic centers for exhaustive confirmation of the diagnosis [2]:

Skin biopsy for advanced studies such as direct and indirect immuno-electron microscopy, microscopy, analysis of the salt-split skin DIF pattern, antigenic mapping by fluorescence overlay, and salt-split skin DIF.
Blood analysis to detect undetectable circulating antibodies specific against Type VII Collagen (Col7), using techniques such as immunoblotting, enzyme-linked immunosorbent assay (ELISA), more detailed IIF, and immunoprecipitation.

The International Bullous Diseases Group (IBDG) has established consensus diagnostic criteria for EBA, which are crucial for confirmation [1,2]. If the clinical and histological presentation of the blistering disease is compatible with EBA, the diagnosis is considered confirmed if two main conditions are met: histological of the blistering disease is compatible with EBA, the diagnosis is considered confirmed if two main conditions are met:

Demonstration of linear deposition of IgG and/or C3 along the basement membrane zone by direct immunofluorescence (DIF).
Detection of anti-COL7 autoantibodies in the patient's serum (by enzyme-linked immunosorbent assay).

Differential Diagnosis of Epidermolysis Bullosa Acquisita

EBA presents a diagnostic challenge, as it can mimic the clinical appearance of other inflammatory blistering diseases. The conditions most frequently considered in the differential diagnosis include bullous pemphigoid and bullous systemic lupus erythematosus (the latter also associated with anti-Col7 autoantibodies).

When contrasting EBA with bullous pemphigoid, EBA is distinguished by several key features [2]:

It tends to manifest in younger individuals, generally under 70 years of age.
It presents prominent involvement of the head and neck.
It frequently involves the mucous membranes.
Skin lesions tend to heal leaving noticeable scars and milia formation.

Treatment Options for Epidermolysis Bullosa Acquisita

The The primary in the management of EBA is twofold: protecting the skin to stop the formation of new blisters and simultaneously promoting the healing of existing lesions to prevent long-term complications.

Since EBA is classified as an autoimmune disease, the use of immunosuppressive immunosuppressive agents

A biopsy may reveal deposits of
Dapsone
Colchicine
Corticosteroids
Mycophenolate Mofetil
Images of Pigmentary Lichen Planus
Intravenous immunoglobulin.

Due to the rarity of this condition, establishing with certainty which of these drugs offers maximum efficacy remains a clinical challenge.

In addition to immunosuppressive treatment, there are other fundamental management strategies for the patient's quality of life:

Proactive treatment of any underlying systemic disease.
Coordination and consultation with specialists such as dentists and ophthalmologists, ophthalmologists, depending on the location of the lesions.
Implementing strict measures to avoid direct physical trauma to vulnerable skin surfaces.
In patients with oral involvement, advice should be given to avoid consuming excessively hard, brittle, or highly acidic foods.

Prognosis of Epidermolysis Bullosa Acquisita

EBA is characterized as a chronic inflammatory dermatosis that proceeds in cycles of remissions partial remissions and exacerbations. exacerbations. With appropriate treatment and rigorous care, patients have the expectation of leading a normal life. However, there are potential risks to manage, including:

Risk of secondary Risk of infection.
Development of severe scars that can lead to joint physical deformities and limitation of range of motion.
Periodontal complications.
Risk of conjunctival scarring that can progress to blindness.
Possible side effects from long-term immunosuppressive medication.

Comprehensive management and control of EBA-specific autoantibodies are essential to positively influence the long-term prognosis of patients affected by this rare disease.